CLSN Celsion

Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Company profile
Ticker
CLSN
Exchange
Website
CEO
Michael Tardugno
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CHEUNG LABORATORIES INC
SEC CIK
Corporate docs
IRS number
521256615
CLSN stock data
()
News
Celsion's Ovarian Cancer Immunotherapy Shows 41% Improvement In R0 Resection Rates
1 Apr 21
Celsion Says Poster On Co's Phase I/II OVATION 2 Study Presented At Society Of Gynecologic Oncology Virtual Annual Meeting On Women's Canver
1 Apr 21
Why VTSI Stock AND CLSN Stock Are Trading Lower Today
31 Mar 21
12 Health Care Stocks Moving In Wednesday's Intraday Session
31 Mar 21
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
31 Mar 21
Press releases
CELSION CORPORATION ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING
5 Apr 21
Celsion Corp. to Host Earnings Call
19 Mar 21
Celsion Corporation Reports 2020 Financial Results and Provides Business Update
19 Mar 21
Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021
12 Mar 21
Poster on Celsion Corporation's Phase I/II OVATION 2 Study to be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women's Cancer
2 Mar 21
Investment data
Securities sold
Number of investors
Calendar
19 Mar 21
12 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from Celsion earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.16M | 17.16M | 17.16M | 17.16M | 17.16M | 17.16M |
Cash burn (monthly) | 391.85K | (positive/no burn) | 1.6M | 1.54M | 1.24M | 1.3M |
Cash used (since last report) | 1.34M | n/a | 5.46M | 5.26M | 4.25M | 4.45M |
Cash remaining | 15.83M | n/a | 11.7M | 11.9M | 12.91M | 12.72M |
Runway (months of cash) | 40.4 | n/a | 7.3 | 7.7 | 10.4 | 9.8 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Mar 21 | Chow Pok Yu Augustine | Option to Purchase Celsion Corporation Common Stock Celsion Corporation Common Stock | Grant | Aquire A | No | No | 2.24 | 40,000 | 89.6K | 183,689 |
19 Mar 21 | Hooper Robert W | Option to Purchase Celsion Corporation Common Stock Celsion Corporation Common Stock | Grant | Aquire A | No | No | 2.24 | 40,000 | 89.6K | 179,737 |
19 Mar 21 | Fritz Frederick J. | Option to Purchase Celsion Corporation Common Stock Celsion Corporation Common Stock | Grant | Aquire A | No | No | 2.24 | 40,000 | 89.6K | 180,118 |
19 Mar 21 | Braun Donald P | Option to Purchase Celsion Corporation Common Stock Celsion Corporation Common Stock | Grant | Aquire A | No | No | 2.24 | 40,000 | 89.6K | 151,357 |
19 Mar 21 | Voss Andreas | Option to Purchase Celsion Corporation Common Stock Celsion Corporation Common Stock | Grant | Aquire A | No | No | 2.24 | 40,000 | 89.6K | 151,357 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|
Financial report summary
?Competition
Codiak BiosciencesManagement Discussion
- Comparison of Fiscal Year Ended December 31, 2020 and Fiscal Year Ended December 31, 2019.
- For the year ended December 31, 2020, our net loss was $21.5 million compared to a net loss of $16.9 million for the year ended December 31, 2019. The Company recognized $1.85 million and $1.82 million in tax benefits from the sale of its New Jersey net operating losses under the Technology Business Tax Certificate Program in each of the fourth quarters of 2020 and 2019, respectively. With $17.2 million in cash and cash equivalents, coupled with approximately $43 million of gross proceeds received from the sale of equity in the first quarter of 2021 and up to $1.85 million in expected proceeds from the sale of the State of New Jersey net operating losses it applied for in 2020, the Company believes it has sufficient capital resources to fund its operations through 2023.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Abbott, abundance, admitting, advisor, AKS, Alba, Allied, Altium, Alto, AMEDIX, amenable, Amersham, analyzing, Anthra, antibody, antigen, Arizona, assumption, Asta, AstraZeneca, attendance, attended, attending, Ayrton, bachelor, backdating, Basel, Bausch, Bayer, behavior, Behring, Biden, Bill, biographical, biology, Biomedical, Biomira, biopharma, bioterrorism, bladder, Boehringer, bold, Bonaventure, book, boost, boundary, Box, Brazil, breadth, Broadway, Brookline, brought, Brunswick, built, calendar, caption, captioned, career, carefully, Caribbean, carrier, cast, Cayman, Centocor, CEO, certified, certify, CFO, chain, Chicago, CIC, circumstance, clarification, claw, COBRA, Coleman, column, COMP, compatible, concept, conduit, confluence, constantly, constitutionality, constructively, contemplated, content, contest, CRADA, crossed, CSL, cum, CVI, cyclophosphamide, Cytogen, Dassault, dealer, delegate, delegated, delegation, demographic, denominated, deployment, detriment, diagnostic, dictating, Diego, disability, discharging, disregarding, dissolution, distancing, Dkt, doctoral, dollar, double, dozen, Dutch, earliest, easily, economy, eighteen, emphasizing, engineering, entry, eventual, eventually, evolutionary, exacerbate, excessive, excise, excitement, exciting, excusing, expressly, extinguishment, faith, fault, fellow, Fidler, FL, Floor, footnote, forensic, founder, Francisco, freedom, frozen, Fundacao, GeneMedicine, GenVec, George, Getulio, GmbH, GP, graduate, Grand, guideline, Hamburg, Harmony, Harvard, heading, hearing, helper, Hoffmann, House, household, Houston, humoral, immunology, Importantly, impressive, IMS, incumbent, inflammatory, insider, Insight, Inspector, intradermally, intramuscularly, intratumoral, invoiced, ITT, Japanese, Jessen, job, jointly, Joseph, judgement, justify, Kaisun, KGA, Khatri, Kobinger, laude, leadership, Legislature, lender, lent, liaison, lifetime, likelihood, Lincoln, linked, literacy, Lomb, London, LP, LPC, lump, Magnetic, Mannheim, marginally, Marine, Martin, Master, MBA, mBC, Medica, Medidata, Mercer, Merck, Meridian, merit, MFN, MFS, Microbiology, mimic, misleading, mitomycin, monotherapy, monovalent, motivate, mouse, MSc, multifunctional, multiplying, multitude, multivalent, mutation, mutational, Mylan, narrative, Nest, NeuroDx, neurosurgery, neutralizing, ninety, noncash, nonrenewal, Novavax, nuclear, nucleocapsid, NY, occasional, Ohio, opposed, opsonization, organizational, orientation, Outboard, outright, Overview, owner, pancreatic, PanDox, parallel, pathogen, Paulo, Paycheck, payroll, pecuniary, peer, pension, people, Pfizer, Pharma, philosophy, PLACCINE, plaintiff, pledging, Plough, podiatric, polymeric, postdoctoral, PPP, premedical, pro, promissory, promptly, propensity, properly, prophylactic, proportionate, prudent, purview, quantify, Radford, rata, ratification, reapplied, reappointed, reassessed, reconsideration, redoubling, regain, regained, Regression, relaying, renamed, renegotiate, repaid, repayment, reposition, resignation, Resonance, retention, retired, retirement, retroactive, revolutionize, Roche, rollout, routinely, running, Rush, Sandoz, Sao, Sarnoff, SBA, SCA, Schering, science, Segregated, sequence, Serono, Shortly, Silicon, simple, sliding, Society, Songbird, sound, sounding, spanning, Spar, SPC, Spike, spun, Squibb, staffing, staggered, stake, Sterling, stimulate, subcutaneously, successor, sum, summa, Super, surface, survey, tactical, Taiho, talent, talented, taxation, tenure, tool, Town, traditional, TSX, twelfth, twenty, Ugland, undergraduate, underway, unexercised, unprecedented, unregistered, unrestricted, untrue, unusual, unvested, uptake, upward, urge, urgent, USA, vacancy, vaccine, Valeo, Valley, vast, vigorously, vii, virtual, vote, voted, voting, VP, Waterhouse, web, welfare, Wesley, West, whatsoever, William, Winthrop, yearly, York, ZLB
Removed:
Argentina, ATM, balanced, BCNU, brain, Bulgaria, CA, Cantor, CCNU, clearer, collected, conferring, confirming, Croatia, cumulated, Czech, Daegu, Denmark, deposited, dividend, dwell, enabling, escalating, Estonia, examined, exempt, Finland, Fitzgerald, formal, Gastroenterology, Greece, Hepatology, hoc, Hungary, incremental, Ireland, Israel, Korea, Kyungpook, largest, Latvia, launched, Lithuania, maker, Malta, matrix, mild, minimizing, modeling, OfferingSM, pegylation, perpetual, persuasive, Peru, Poland, Portugal, preferentially, presence, principle, progressive, prompted, radio, readout, registrational, Republic, Romania, Russia, simulation, Singapore, Slovakia, Slovenia, SM, split, sRFA, strongly, suffering, suggest, Sweden, Taiwan, Tak, unpredictable, unresectable, Vietnam, Won, write, Young, Zealand
Financial reports
10-K
2020 FY
Annual report
19 Mar 21
10-Q
2020 Q3
Quarterly report
16 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
15 May 20
10-K
2019 FY
Annual report
25 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
15 May 19
10-K
2018 FY
Annual report
29 Mar 19
10-Q
2018 Q3
Quarterly report
14 Nov 18
Current reports
8-K
Celsion Corporation Announces $15 Million Registered Direct Offering
2 Apr 21
8-K
Celsion Corporation Reports 2020 Financial Results and Provides Business Update
19 Mar 21
8-K
Celsion Corporation Issues Letter to Stockholders
11 Feb 21
8-K
Other Events
3 Feb 21
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Jan 21
8-K
Celsion Corporation Announces $35 Million Registered Direct Offering Priced At-the-market Under Nasdaq Rules
25 Jan 21
8-K
Termination of a Material Definitive Agreement
21 Jan 21
8-K
Departure of Directors or Certain Officers
31 Dec 20
8-K
Celsion Corporation Reports Third Quarter 2020 Financial Results and Provides Business Update
16 Nov 20
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Oct 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
2 Apr 21
S-3
Shelf registration
19 Mar 21
424B5
Prospectus supplement for primary offering
25 Jan 21
424B5
Prospectus supplement for primary offering
25 Jan 21
S-3
Shelf registration
9 Oct 20
424B5
Prospectus supplement for primary offering
8 Sep 20
S-3/A
Shelf registration (amended)
11 Aug 20
S-8
Registration of securities for employees
31 Jul 20
S-3
Shelf registration
31 Jul 20
424B5
Prospectus supplement for primary offering
22 Jun 20
Proxies
PRER14A
Preliminary revised proxy
12 Apr 21
PRE 14A
Preliminary proxy
8 Apr 21
DEF 14A
Definitive proxy
29 Apr 20
DEF 14A
Definitive proxy
29 Mar 19
DEF 14A
Definitive proxy
29 Mar 18
DEF 14A
Definitive proxy
3 Apr 17
PRE 14A
Preliminary proxy
19 Mar 17
DEF 14A
Definitive proxy
4 May 16
PRE 14A
Preliminary proxy
24 Apr 16
DEF 14A
Definitive proxy
29 Apr 15
Other
EFFECT
Notice of effectiveness
31 Mar 21
EFFECT
Notice of effectiveness
28 Oct 20
CORRESP
Correspondence with SEC
22 Oct 20
UPLOAD
Letter from SEC
15 Oct 20
EFFECT
Notice of effectiveness
14 Aug 20
CORRESP
Correspondence with SEC
10 Aug 20
UPLOAD
Letter from SEC
6 Aug 20
EFFECT
Notice of effectiveness
29 Nov 19
CORRESP
Correspondence with SEC
25 Nov 19
EFFECT
Notice of effectiveness
15 Oct 18
Ownership
4
Celsion / Timothy J Tumminello ownership change
22 Mar 21
4
Celsion / JEFFREY WAYNE CHURCH ownership change
22 Mar 21
4
Celsion / Michael H Tardugno ownership change
22 Mar 21
4
Celsion / Andreas Voss ownership change
22 Mar 21
4
Celsion / Donald P Braun ownership change
22 Mar 21
4
Celsion / Frederick J. Fritz ownership change
22 Mar 21
4
Celsion / Robert W Hooper ownership change
22 Mar 21
4
Celsion / Pok Yu Augustine Chow ownership change
22 Mar 21
SC 13G
Celsion / Ayrton Capital ownership change
1 Feb 21
SC 13G
Celsion / Altium Capital Management ownership change
29 Jan 21
Transcripts
2020 Q4
Earnings call transcript
19 Mar 21
2020 Q3
Earnings call transcript
16 Nov 20
2020 Q2
Earnings call transcript
14 Aug 20
2020 Q1
Earnings call transcript
15 May 20
2019 Q4
Earnings call transcript
26 Mar 20
2019 Q3
Earnings call transcript
15 Nov 19
2019 Q2
Earnings call transcript
15 Aug 19
2019 Q1
Earnings call transcript
15 May 19
2018 Q4
Earnings call transcript
29 Mar 19
2018 Q3
Earnings call transcript
15 Nov 18
Reddit threads
Daily Plays - March 22, 2021
22 Mar 21
Daily Discussion Thread - March 19th, 2021
19 Mar 21
Daily Discussion Thread - March 18th, 2021
18 Mar 21
Daily Discussion Thread - March 17th, 2021
17 Mar 21
Morning Update for Tuesday, 03/16/21
16 Mar 21
Most Anticipated Earnings Releases for the week beginning March 15th, 2021
15 Mar 21
Daily Plays - March 12, 2021
12 Mar 21
Daily Plays - March 11, 2021
11 Mar 21
Anyone else go on a shopping spree today?
9 Mar 21
SNGX potentially to the moon with their heat-stable COVID vaccine candidate, avoiding refrigeration or freezing
4 Mar 21